ORLANDO, FLA. — Increasing levels of protein and fiber, stressing portion control and adding savory flavors are ways that ...

HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.

GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

US sweet protein startup Oobli has raised $18M and partnered with global ingredients giant Ingredion to develop ...

If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...

The case for GLP-1 drugs like Ozempic possibly causing blindness is building. A new paper out this week describes several people who developed eye conditions soon after they began taking semaglutide ...

More and more Americans are turning to GLP-1 injections to lose weight. FOX 7 Austin's Rebecca Thomas spoke to an Austin physician to discuss.

The drug semaglutide has been linked to a lower risk of alcoholism before, but now we have strong evidence that it really ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...